



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of

Attorney Docket No. 38005-0121

Roland KONTERMANN et al.

Confirmation No. 7814

Serial No. 09/288,719

Group Art Unit: 1632

Filed: April 9, 1999

Examiner: A. Beckerleg

For: SINGLE-CHAIN MULTIPLE ANTIGEN-BINDING MOLECULE, ITS  
PREPARATION AND USE

1632  
Box 550  
#31 5  
7-2-02  
P. 2,  
**RECEIVED**

JUN 28 2002

TECH CENTER 1600/2900

**AMENDMENT IN RESPONSE TO NOTICE**  
**UNDER 37 CFR §§ 1.821 – 1.825**

Commissioner for Patents  
Washington, D.C. 20231  
**Box SEQUENCE**

Sir:

In response to the Notice to Comply with Requirements for Patent Applications  
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed June 4, 2002,  
please amend the application as follows:

**IN THE SPECIFICATION:**

**Page 10, between paragraphs 1 and 2:** Please amend as follows:

--The following fusogenic peptides disclosed in DE 196 49 645.4, are listed on page 10,  
lines 30-64:

- (1) peptide containing the peptide GLFEALLELLESLWELLLEA (SEQ ID NO: 20)  
(Gottschalk *et al.*, *Gene Ther.* 3: 448 (1996));
- (2) peptide containing the peptide AALAEA[LAEA]<sub>4</sub>LAAAGC (SEQ ID NO: 21) (Acm)  
(Wang *et al.*, *Technol. Advances in Vector Syst. For Gene Ther.*, May 6-7, 1996,  
Coronado, IBC Conference);
- (3) peptide containing the peptide FAGV-VLAGAALGVAAAAQI (SEQ ID NO: 22) of  
the fusion protein of measles-virus (Yeagle *et al.*, *Biochem. Biophys. Acta* 1065, 49  
(1991));